Hybio Pharmaceutical Company
Shenzhen Hybio Pharmaceutical Co., Ltd. (翰宇药业) is a high-tech enterprise which is engaged in research, development, production, and sales of polypeptide drugs. On the basis of strict production management and quality control according to the GMP strictly, it breaks through the bottle-neck of the polypeptide drugs' large-scale production technology by means of introduction digestion, independent innovation, and any other patterns. Shenzhen Hybio Pharmaceutical has successively applied for 38 patents, with 5 patents for invention, 7 national new drug certificates, 5 new drug clinical trial permissions, and 45 drug registration letters. The drugs are mainly used to treat diseases such as digestive diseases, cardiovascular and cerebrovascular diseases, diabetes, infectious diseases, tumors, senile diseases, and more.
Technology:
Small Molecules
Industry:
PharmTech
Headquarters:
Shenzhen, Guangdong, China
Zip:
501-1000
Founded Date:
1998-01-01
Employees Number:
501-1000
Funding Status:
IPO
Acquisitions Number:
2
Investors Number:
13870170
Total Funding:
13870170
Estimated Revenue:
2011-04-15
Last Funding Date:
Series B
Last Funding Type:
Series B
Register and Claim Ownership